FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2499859474> ?p ?o ?g. }

• W2499859474 endingPage "871" @default.
• W2499859474 startingPage "871" @default.
• W2499859474 abstract "Abstract Bortezomib, a proteasome inhibitor, is extremely effective for the treatment of multiple myeloma (MM). However, nearly all patients will eventually become refractory to bortezomib. Vorinostat is a potent inhibitor of histone deacetylase enzymes, and has been shown to affect growth of various cell lines, including MM, in a variety of in vitro non-clinical studies. Furthermore, the combination of bortezomib and vorinostat has demonstrated synergy in several in vitro and murine models. Subsequently, 2 multicenter, open-label, Phase I clinical trials have been conducted to investigate the combination of vorinostat with bortezomib in patients with MM. In the first trial, 34 patients with relapsed/refractory MM were enrolled. Patients received escalating doses of vorinostat (200 mg bid or 300–400 mg daily for 14 days) and bortezomib (0.7, 0.9, 1.1, or 1.3 mg/m2 on days 1, 4, 8, and 11); cycles were repeated every 21 days for ≤8 cycles or until progressive disease (PD) or intolerable toxicity. In the event of PD, oral dexamethasone (20 mg on days 1–4 and 17–20) could be added to the bortezomib plus vorinostat combination. The highest dose level of vorinostat was 400 mg daily for 14 days and bortezomib 1.3 mg/m2. The maximum tolerated dose (MTD) was not determined because ≥2 dose-limiting toxicities (DLTs) did not occur at any dose level. The most common drug-related adverse events were nausea (61.8%), diarrhea (58.8%), thrombocytopenia (50%), and vomiting (50%). Two patients experienced a DLT; grade 3 transient AST elevation was experienced by 1 patient receiving 400 mg vorinostat daily and 0.9 mg/m2 bortezomib, and grade 4 thrombocytopenia was experienced by 1 patient receiving 400 mg vorinostat daily and 1.3 mg/m2 bortezomib. Among 34 evaluable patients, the best response to vorinostat plus bortezomib was a partial response (PR) in 9 (26%) patients, minimal response (MR) in 7 (21%) patients, and stable disease (SD) in 18 (53%) patients. Mean duration of SD was 89 days, range 9–369 days. Of the 13 evaluable patients who had previously been treated with bortezomib, 5 achieved a PR, 1 had a MR, and 7 had SD. The effect of adding dexamethasone will also be analyzed and presented. The second trial enrolled 23 patients who received vorinostat (100–500 mg on days 4–11) and bortezomib (1–1.3 mg/m2 on days 1, 4, 8, and 11). Dexamethasone was added at cycle 2 for 6 patients who achieved less than a PR, and at cycle 4 for 5 patients with PD and at cycle 6 for 2 patients with PD. There was no upgrade in response for any patients who received additional dexamethasone. Two patients in the vorinostat 500 mg group experienced DLT (fatigue and prolonged QTc); MTD was identified as vorinostat 400 mg plus bortezomib 1.3 mg/m2. The main toxicities in this trial were hematologic (anemia, neutropenia, and thrombocytopenia). Twenty-one patients were evaluable for response (2 achieved very good PR, 7 PR, 10 SD, 2 progressive PD). Of the 9 patients who were refractory to bortezomib, 3 had PR, 4 had SD, 1 had PD, and 1 was non-evaluable. Co-administration of bortezomib did not alter the pharmacokinetics of vorinostat. In conclusion, these data suggest that the combination of vorinostat plus bortezomib is active for treatment of MM, even among some patients with prior exposure to bortezomib." @default.
• W2499859474 created "2016-08-23" @default.
• W2499859474 creator A5008279667 @default.
• W2499859474 creator A5023752321 @default.
• W2499859474 creator A5027363771 @default.
• W2499859474 creator A5028046297 @default.
• W2499859474 creator A5032464400 @default.
• W2499859474 creator A5037047474 @default.
• W2499859474 creator A5037221378 @default.
• W2499859474 creator A5055929208 @default.
• W2499859474 creator A5064710410 @default.
• W2499859474 date "2008-11-16" @default.
• W2499859474 modified "2023-10-18" @default.
• W2499859474 title "Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience" @default.
• W2499859474 doi "https://doi.org/10.1182/blood.v112.11.871.871" @default.
• W2499859474 hasPublicationYear "2008" @default.
• W2499859474 type Work @default.
• W2499859474 sameAs 2499859474 @default.
• W2499859474 citedByCount "25" @default.
• W2499859474 countsByYear W24998594742012 @default.
• W2499859474 countsByYear W24998594742013 @default.
• W2499859474 crossrefType "journal-article" @default.
• W2499859474 hasAuthorship W2499859474A5008279667 @default.
• W2499859474 hasAuthorship W2499859474A5023752321 @default.
• W2499859474 hasAuthorship W2499859474A5027363771 @default.
• W2499859474 hasAuthorship W2499859474A5028046297 @default.
• W2499859474 hasAuthorship W2499859474A5032464400 @default.
• W2499859474 hasAuthorship W2499859474A5037047474 @default.
• W2499859474 hasAuthorship W2499859474A5037221378 @default.
• W2499859474 hasAuthorship W2499859474A5055929208 @default.
• W2499859474 hasAuthorship W2499859474A5064710410 @default.
• W2499859474 hasConcept C104317684 @default.
• W2499859474 hasConcept C126322002 @default.
• W2499859474 hasConcept C142424586 @default.
• W2499859474 hasConcept C143998085 @default.
• W2499859474 hasConcept C185592680 @default.
• W2499859474 hasConcept C197934379 @default.
• W2499859474 hasConcept C2776262904 @default.
• W2499859474 hasConcept C2776364478 @default.
• W2499859474 hasConcept C2776694085 @default.
• W2499859474 hasConcept C2777478702 @default.
• W2499859474 hasConcept C2778305200 @default.
• W2499859474 hasConcept C2778367456 @default.
• W2499859474 hasConcept C2778822529 @default.
• W2499859474 hasConcept C2780401358 @default.
• W2499859474 hasConcept C2780580376 @default.
• W2499859474 hasConcept C2780852908 @default.
• W2499859474 hasConcept C55493867 @default.
• W2499859474 hasConcept C64927066 @default.
• W2499859474 hasConcept C71924100 @default.
• W2499859474 hasConcept C86803240 @default.
• W2499859474 hasConcept C87355193 @default.
• W2499859474 hasConcept C90924648 @default.
• W2499859474 hasConcept C98274493 @default.
• W2499859474 hasConceptScore W2499859474C104317684 @default.
• W2499859474 hasConceptScore W2499859474C126322002 @default.
• W2499859474 hasConceptScore W2499859474C142424586 @default.
• W2499859474 hasConceptScore W2499859474C143998085 @default.
• W2499859474 hasConceptScore W2499859474C185592680 @default.
• W2499859474 hasConceptScore W2499859474C197934379 @default.
• W2499859474 hasConceptScore W2499859474C2776262904 @default.
• W2499859474 hasConceptScore W2499859474C2776364478 @default.
• W2499859474 hasConceptScore W2499859474C2776694085 @default.
• W2499859474 hasConceptScore W2499859474C2777478702 @default.
• W2499859474 hasConceptScore W2499859474C2778305200 @default.
• W2499859474 hasConceptScore W2499859474C2778367456 @default.
• W2499859474 hasConceptScore W2499859474C2778822529 @default.
• W2499859474 hasConceptScore W2499859474C2780401358 @default.
• W2499859474 hasConceptScore W2499859474C2780580376 @default.
• W2499859474 hasConceptScore W2499859474C2780852908 @default.
• W2499859474 hasConceptScore W2499859474C55493867 @default.
• W2499859474 hasConceptScore W2499859474C64927066 @default.
• W2499859474 hasConceptScore W2499859474C71924100 @default.
• W2499859474 hasConceptScore W2499859474C86803240 @default.
• W2499859474 hasConceptScore W2499859474C87355193 @default.
• W2499859474 hasConceptScore W2499859474C90924648 @default.
• W2499859474 hasConceptScore W2499859474C98274493 @default.
• W2499859474 hasIssue "11" @default.
• W2499859474 hasLocation W24998594741 @default.
• W2499859474 hasOpenAccess W2499859474 @default.
• W2499859474 hasPrimaryLocation W24998594741 @default.
• W2499859474 hasRelatedWork W2058808800 @default.
• W2499859474 hasRelatedWork W2072994817 @default.
• W2499859474 hasRelatedWork W2096858205 @default.
• W2499859474 hasRelatedWork W2124042268 @default.
• W2499859474 hasRelatedWork W230412469 @default.
• W2499859474 hasRelatedWork W2362636202 @default.
• W2499859474 hasRelatedWork W2364188423 @default.
• W2499859474 hasRelatedWork W2373162333 @default.
• W2499859474 hasRelatedWork W2531713994 @default.
• W2499859474 hasRelatedWork W3105812043 @default.
• W2499859474 hasVolume "112" @default.
• W2499859474 isParatext "false" @default.
• W2499859474 isRetracted "false" @default.
• W2499859474 magId "2499859474" @default.
• W2499859474 workType "article" @default.